Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, an oral treatment for schizophrenia.
Subscribe to our email newsletter
The patent will extend coverage period by at least until 2031, which is nine years longer than the granted patent coverage earlier to the company.
The patent applications for the product are awaiting approval in Europe, Japan, India, China, Brazil, Mexico, Canada, Australia and Israel.
BioLineRx CEO Kinneret Savitsky said the company is pleased with the allowance of the patent covering BL-1020’s crystalline form by the USPTO.
”This approval, together with recent additional patent approvals regarding BL-1020 and other drug candidates, is a testament to our focused and highly professional patent application strategy," Savitsky added.
"Today, almost 1% of the world’s population suffers from schizophrenia, most of whom suffer concomitant cognitive impairment that may severely affect daily functioning.”